Aurobindo Pharma Limited announced the completion of a United States Food and Drug Administration (US FDA) inspection at Unit-IV of its wholly-owned subsidiary, APL Healthcare Limited. The inspection took place from December 08 to December 17, 2025, at the facility located in Palchur village and part of Palepalem Village, Naidupeta Mandal, SPSR Nellore District, Andhra Pradesh. Following the inspection, the US FDA issued a Form 483 with five observations. The company has stated that these observations are procedural in nature and that it will provide a response to the US FDA within the stipulated timelines. Aurobindo Pharma reiterated its commitment to upholding the highest quality manufacturing standards across all its global facilities. The company has also indicated that this development is not expected to have any impact on the financial or operational activities of the facility. They will keep the stock exchanges informed of any further developments.